JP2009520690A5 - - Google Patents

Download PDF

Info

Publication number
JP2009520690A5
JP2009520690A5 JP2008543539A JP2008543539A JP2009520690A5 JP 2009520690 A5 JP2009520690 A5 JP 2009520690A5 JP 2008543539 A JP2008543539 A JP 2008543539A JP 2008543539 A JP2008543539 A JP 2008543539A JP 2009520690 A5 JP2009520690 A5 JP 2009520690A5
Authority
JP
Japan
Prior art keywords
amino
dihydroxyphenyl
phenylcarbonyloxypropyl
propanoate
propanoate mesylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008543539A
Other languages
English (en)
Japanese (ja)
Other versions
JP5153641B2 (ja
JP2009520690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/046273 external-priority patent/WO2007067495A2/en
Publication of JP2009520690A publication Critical patent/JP2009520690A/ja
Publication of JP2009520690A5 publication Critical patent/JP2009520690A5/ja
Application granted granted Critical
Publication of JP5153641B2 publication Critical patent/JP5153641B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008543539A 2005-12-05 2006-12-04 レボドパプロドラッグメシラート、その組成物、およびその使用法 Expired - Fee Related JP5153641B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74187605P 2005-12-05 2005-12-05
US60/741,876 2005-12-05
PCT/US2006/046273 WO2007067495A2 (en) 2005-12-05 2006-12-04 Levodopa prodrug mesylate, compositions thereof, and uses thereof

Publications (3)

Publication Number Publication Date
JP2009520690A JP2009520690A (ja) 2009-05-28
JP2009520690A5 true JP2009520690A5 (https=) 2010-01-21
JP5153641B2 JP5153641B2 (ja) 2013-02-27

Family

ID=38123406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543539A Expired - Fee Related JP5153641B2 (ja) 2005-12-05 2006-12-04 レボドパプロドラッグメシラート、その組成物、およびその使用法

Country Status (20)

Country Link
US (5) US7563821B2 (https=)
EP (1) EP1959948B1 (https=)
JP (1) JP5153641B2 (https=)
KR (1) KR101396639B1 (https=)
CN (1) CN101365439B (https=)
AU (1) AU2006322051B2 (https=)
BR (1) BRPI0619425A2 (https=)
CA (1) CA2631643C (https=)
CY (1) CY1113108T1 (https=)
DK (1) DK1959948T3 (https=)
ES (1) ES2391575T3 (https=)
IL (1) IL191937A (https=)
NO (1) NO20082768L (https=)
NZ (1) NZ569485A (https=)
PL (1) PL1959948T3 (https=)
PT (1) PT1959948E (https=)
RU (1) RU2429223C2 (https=)
TW (1) TWI403493B (https=)
WO (1) WO2007067495A2 (https=)
ZA (1) ZA200805511B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2365580C2 (ru) * 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
US7323585B2 (en) 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
TWI403493B (zh) * 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
WO2008034087A2 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US8802681B2 (en) 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
US8784847B2 (en) * 2009-04-17 2014-07-22 Merz Pharma Gmbh & Co. Kgaa Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
AU2011222856B2 (en) 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
EP2647619B1 (en) 2010-12-02 2015-01-21 Ono Pharmaceutical Co., Ltd. Novel compound and medical use thereof
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
WO2012096886A1 (en) 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
AU2012225337B2 (en) 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
CA2853251A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable rasagiline compositions and methods of treatment thereof
US9575244B2 (en) 2013-01-04 2017-02-21 Bal Makund Dhar Light guide apparatus and fabrication method thereof
FR3008411B1 (fr) 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
CN103554078B (zh) * 2013-11-22 2016-03-02 浙江安赛生物科技有限公司 低级醛（c2-c10）丙二醇缩醛的合成方法
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
MY190011A (en) 2016-04-11 2022-03-22 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
HRP20221279T1 (hr) 2016-07-14 2022-12-23 Crinetics Pharmaceuticals, Inc. Modulatori somatostatina i njihove uporabe
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
EP3849533A4 (en) 2018-09-13 2022-06-22 University of Canberra PROCEDURE FOR INHIBITION
CA3107139C (en) * 2018-09-21 2023-01-03 Kashiv Biosciences, Llc Extended release compositions comprising trihexyphenidyl
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
EP3999509A4 (en) * 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
FI4210700T3 (fi) 2020-09-09 2025-09-16 Crinetics Pharmaceuticals Inc Somatostatiinimodulaatorin formulaatioita
WO2022056360A1 (en) * 2020-09-11 2022-03-17 Synagile Corporation Methods for continuous oral drug delivery
US12599578B2 (en) 2021-03-09 2026-04-14 Ensysce Biosciences Inc. Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
CN116500162A (zh) * 2023-04-27 2023-07-28 北京和合医学诊断技术股份有限公司 一种同时检测6种药物浓度的液相色谱-质谱分析方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3983138A (en) 1973-09-25 1976-09-28 Merck & Co., Inc. Amino acid esters
US4038411A (en) 1973-09-25 1977-07-26 Merck & Co., Inc. Antihypertensive amino acid esters
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
FR2365341A1 (fr) 1976-09-28 1978-04-21 Synthelabo Derives de l'acide l-(phenyl-3 amino-2 propionyloxy)-2 acetique
US4180509A (en) * 1977-07-01 1979-12-25 Merrell Toraude Et Compagnie α-Ethynyl tryptophanes
US4311706A (en) 1980-01-22 1982-01-19 Interx Research Corporation Novel dopa/dopamine prodrugs
JPS5824547A (ja) 1981-08-06 1983-02-14 Nippon Zoki Pharmaceut Co Ltd 新規アミノ酸誘導体
US4914222A (en) 1983-08-29 1990-04-03 Merck & Co., Inc. Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process
LU85757A1 (fr) 1985-02-04 1986-09-02 Univ Catholique Louvain Derives nouveaux de la l-dopa,procedes pour leur preparation et compositions pharmaceutiques concernant de tels composes
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4873263A (en) 1985-12-30 1989-10-10 Merck & Co., Inc. Rectally absorbable form of L-dopa
JPS62258347A (ja) * 1986-05-02 1987-11-10 Banyu Pharmaceut Co Ltd 無水結晶形態のｌ−スレオ−３−（３，４−ジヒドロキシフエニル）−ｎ−メチルセリン
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4983400A (en) 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
JPH07278076A (ja) * 1994-04-12 1995-10-24 Ajinomoto Co Inc Ｌ−フェニルアラニン・モノメチル硫酸塩の晶析方法
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB2348371B (en) 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
WO2002028411A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
AU2001296703A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030158254A1 (en) 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
AU2003293423A1 (en) * 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
RU2365580C2 (ru) * 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
TWI403493B (zh) * 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
WO2008034087A2 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2011056240A2 (en) * 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use

Similar Documents

Publication Publication Date Title
JP2009520690A5 (https=)
RU2008127312A (ru) Мезилатное пролекарство леводопы, его композиции и применение
JP5248331B2 (ja) 重水素化カテコールアミン誘導体およびその化合物を含む薬剤
AU2015336400B2 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
JP2011527333A5 (https=)
US11046640B2 (en) Water-soluble L-DOPA esters
JP2019515024A (ja) ボルチオキセチンのパモ酸塩及びその結晶形
RU2020117345A (ru) Твердая форма валбеназина
JP2014530818A5 (https=)
JP2018193356A (ja) 重水素化カテコールアミン誘導体ならびにそれらの化合物を含有する医薬品
JP2013538849A5 (https=)
IL259572A (en) Tetracycline salts
AU2009350978A1 (en) Lenalidomide salts
AU2011337596A1 (en) Novel compound and medical use thereof
JP2009040767A5 (https=)
TW202233205A (zh) 莫奈皮拉韋之醫藥同質異晶物
JP5378499B2 (ja) 微小管形成阻害剤として有用なベンゾフェノンチアゾール誘導体及びその製造方法
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
KR20150085513A (ko) (1ｓ,4ｓ,5ｓ)-4-브로모-6-옥사바이시클로[3.2.1]옥탄-7-온의 제조 방법
JPWO2020099923A5 (https=)
JPWO2015152128A1 (ja) アミノ酸前駆体、アミノ酸およびその製造方法、ならびに該アミノ酸を用いたｐｅｔ診断用トレーサー
EP3126324A1 (en) A process for preparation of levothyroxine and salts thereof
TW200946105A (en) Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
JP2010504943A (ja) ピリドオキサゼピンプロゲステロン受容体モジュレータ